Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Xencor Inc (XNCR)
Xencor Inc (XNCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,466,479
  • Shares Outstanding, K 60,875
  • Annual Sales, $ 164,580 K
  • Annual Income, $ -55,180 K
  • 60-Month Beta 0.70
  • Price/Sales 10.00
  • Price/Cash Flow N/A
  • Price/Book 2.19
Trade XNCR with:

Options Overview Details

View History
  • Implied Volatility 81.97% ( -2.18%)
  • Historical Volatility 58.03%
  • IV Percentile 91%
  • IV Rank 71.44%
  • IV High 112.55% on 01/25/24
  • IV Low 5.52% on 09/18/23
  • Put/Call Vol Ratio 0.65
  • Today's Volume 28
  • Volume Avg (30-Day) 8
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 95
  • Open Int (30-Day) 214

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate 0.36
  • Number of Estimates 6
  • High Estimate 1.89
  • Low Estimate -1.35
  • Prior Year -0.20
  • Growth Rate Est. (year over year) +280.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.26 +31.93%
on 02/05/24
24.85 -3.08%
on 02/20/24
+4.45 (+22.66%)
since 01/19/24
3-Month
17.82 +35.19%
on 12/01/23
24.85 -3.08%
on 02/20/24
+5.59 (+30.22%)
since 11/21/23
52-Week
16.49 +46.09%
on 11/09/23
34.89 -30.95%
on 02/23/23
-10.05 (-29.44%)
since 02/21/23

Most Recent Stories

More News
5 Growth Stocks with 66% Upside Potential or More

Here's a closer look at five growth stocks that analysts expect to rally in 2024 as the Fed prepares to pivot to a more dovish policy stance.

GAMB : 8.70 (-2.90%)
SOUN : 3.77 (-5.51%)
XNCR : 24.09 (+2.51%)
RKLB : 4.64 (-3.93%)
GSAT : 1.6200 (-5.81%)
2 Growth Stocks With 35% to 150% Upside in 2024

While all eyes are on AI stocks, there are a few undervalued growth stocks that have the potential to provide investors with massive long-term returns.

ACB : 3.40 (-2.02%)
CGC : 3.44 (-2.82%)
GTBIF : 13.3200 (-0.30%)
$SPX : 4,981.80 (+0.13%)
CRLBF : 1.6900 (-2.87%)
XNCR : 24.09 (+2.51%)
2 Beaten-Down Growth Stocks With 90% or More Upside Potential in 2024

While these stocks have taken a beating this year, Wall Street believes they have major rebound potential in 2024.

XNCR : 24.09 (+2.51%)
TCNNF : 8.9000 (+2.53%)
Xencor: Q3 Earnings Snapshot

Xencor: Q3 Earnings Snapshot

XNCR : 24.09 (+2.51%)
Xencor: Q2 Earnings Snapshot

Xencor: Q2 Earnings Snapshot

XNCR : 24.09 (+2.51%)
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of -36% and 1.10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

XNCR : 24.09 (+2.51%)
MKGAF : 166.1000 (-1.42%)
Xencor: Q1 Earnings Snapshot

Xencor: Q1 Earnings Snapshot

XNCR : 24.09 (+2.51%)
Xencor Reports First Quarter 2023 Financial Results

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial...

XNCR : 24.09 (+2.51%)
Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release...

XNCR : 24.09 (+2.51%)
Xencor Appoints Nancy Valente, M.D., as Chief Development Officer

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment...

XNCR : 24.09 (+2.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California.

See More

Key Turning Points

3rd Resistance Point 25.44
2nd Resistance Point 24.77
1st Resistance Point 24.43
Last Price 24.09
1st Support Level 23.42
2nd Support Level 22.75
3rd Support Level 22.41

See More

52-Week High 34.89
Fibonacci 61.8% 27.86
Fibonacci 50% 25.69
Last Price 24.09
Fibonacci 38.2% 23.52
52-Week Low 16.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar